Table 1 Baseline patient characteristicsa

From: Clustered repetitive transcranial magnetic stimulation for the prevention of depressive relapse/recurrence: a randomized controlled trial

 

rTMS + ADP (n = 82)

rTMS (n = 91)

ADP (n = 108)

Demographic characteristics

Female, n (%)

60 (73.2)

66 (72.5)

85 (78.7)

Han ethnic origin, n (%)

82 (100)

91 (100)

108 (100)

Age, years

Mean ± SD

42.3 ± 11.4

40.0 ± 11.5

40.9 ± 11.8

Range

19–63

19–64

18–64

Marital status

Single, separated/divorced and widowed, n (%)

14 (17.1)

14 (15.4)

17 (15.7)

Married, n (%)

68 (82.9)

77 (84.6)

91(84.3)

Education

Illiterate and elementary, n (%)

4 (4.8)

3 (3.3)

7 (6.5)

Middle, n (%)

24 (29.3)

24 (26.4)

36 (33.3)

High, n (%)

24 (29.3)

28 (30.7)

23 (21.3)

College and above, n (%)

30 (36.6)

36 (39.6)

42 (38.9)

Employment status

Students, unemployed and retired, n (%)

34 (41.5)

36 (39.6)

36 (33.3)

Employed, n (%)

48 (58.5)

55 (60.4)

72 (66.7)

Clinical characteristics

Family history of mental illness, n (%)

8 (9.7)

2 (2.2)

2 (1.9)

Duration of the illness, months

Mean ± SD

14.5 ± 20.1

10.2 ± 11.3

14.2 ± 22.8

Range

1–120

1–60

1–120

No. of previous depressive episode

0 (first episode), n (%)

51 (62.2)

52 (57.1)

73 (67.6)

1, n (%)

3 (3.7)

11 (12.1)

6 (5.6)

2–4, n (%)

22 (26.8)

27 (29.7)

26 (24.1)

≥5, n (%)

6 (7.3)

1 (1.1)

3 (2.8)3

Antidepressants taken in run-in treatmentb

Paroxetine

53 (64.6)

60 (65.9)

78 (72.2)

Venlafaxine

8 (9.8)

18 (19.8)

19 (17.6)

Escitalopram

7 (8.5)

6 (6.6)

9 (8.3)

Fluoxetine

12 (14.6)

4 (4.4)

2 (1.9)

Sertraline

2 (2.5)

3 (3.3)

0

Symptom severity at entry into run-in treatment

HAMD-17, mean ± SD

22.9 ± 3.6

24.1 ± 3.6

24.0 ± 3.5

CGI-S, mean (SD)

4.5 ± 0.7

4.4 ± 0.7

4.5 ± 0.7

Symptom severity at entry into maintenance treatment

HAMD-17, mean ± SD

6.5 ± 2.2

5.9 ± 3.0

5.8 ± 4.1

CGI-S, mean ± SD

1.3 ± 0.5

1.2 ± 0.4

1.3 ± 0.6

Remission

Full (HAMD-17 ≤ 7), n (%)

55 (67.1)

73 (80.2)

85 (78.7)

Partial (HAMD-17 = 8–14), n (%)

27 (32.9)

18 (19.8)

23 (21.3)

  1. a rTMS repetitive transcranial magnetic stimulation, ADP antidepressants, HAMD-17 the 17-item Hamilton Rating Scale for Depression, CGS Clinical Global Impression-Severity, SD standard deviation
  2. bA significant difference was detected in antidepressants run-in treatment among the three groups (χ 2 = 19.759, d.f. = 8, P = 0.011)